Rheumatoid Arthritis/Systemic Lupus Erythematosus-238392 Part A
Study Dates:
Visit dates are flexible
Study Number
238392
Group
● Smoking (Yes)
● Smoking (No)
● Arthritis
Compensation
Up to: $935
Gender
Male, Female, Smoker, Non-Smoker
Age
18-70
BMI
17.5 - 40
Additional Information
To be eligible for this study you must have been diagnosed with rheumatoid arthritis or systemic lupus erythematosus for at least 6 months. For more information, please complete the online form or call 1-800-797-2448.
Details
The purpose of this study is to assess the safety and tolerability of an investigational drug in subjects with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study drug is a type of antibody that is directed against a specific receptor within the immune system that has been found to be involved in systemic autoimmune diseases such as SLE and RA.
Volunteers in the study will receive a single dose of the study drug via an IV (intravenous) infusion. To determine if you qualify for the study you must first complete a screening visit.
Participation in this study involves 1 screening visit, 1 inpatient admission to our clinic for 2 days/1 night for dosing, and a minimum of 8 outpatient visits spread out over 16 weeks.